Myelofibrosis natural history, complications and prognosis
Myelofibrosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Myelofibrosis natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Myelofibrosis natural history, complications and prognosis |
FDA on Myelofibrosis natural history, complications and prognosis |
CDC on Myelofibrosis natural history, complications and prognosis |
Myelofibrosis natural history, complications and prognosis in the news |
Blogs on Myelofibrosis natural history, complications and prognosis |
Risk calculators and risk factors for Myelofibrosis natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Natural History
Myelofibrosis has a very indolent course.[1]
Complications
Common complications of myelofibrosis include:[2][3][4][5]
- Acute myelogenous leukemia
- Infections
- Bleeding
- Thrombohemorrhagic events
- Hepatic failure
- Heart failure
- Gout
- Progressive marrow failure
- Hypertrophic osteoarthropathy
Prognosis
- Prognosis of myelofibrosis is poor. The median survival for myelofibrosis is 3.5 years to 5.5 years, but patients younger than 55 years have a median survival of 11 years.[5]
References
- ↑ Diagnosis of myelofibrosis. Wikipedia 2016. https://en.wikipedia.org/wiki/Myelofibrosis. Accessed on March 8, 2016
- ↑ Complications of myelofibrosis. US National Library of Medicine 2016. https://www.nlm.nih.gov/medlineplus/ency/article/000531.htm. Accessed on March 7, 2016
- ↑ Signs and symptoms of myelofibrosis. Wikipedia 2016. https://en.wikipedia.org/wiki/Myelofibrosis. Accessed on March 7, 2016
- ↑ Kelle, Bayram; Yıldız, Fatih; Paydas, Semra; Bagır, Emine Kılıc; Ergin, Melek; Kozanoglu, Erkan (2015). "Coexistence of hypertrophic osteoarthropathy and myelofibrosis". Revista Brasileira de Reumatologia (English Edition). doi:10.1016/j.rbre.2014.11.004. ISSN 2255-5021.
- ↑ 5.0 5.1 Disease overview of primary myelofibrosis. National cancer institute 2016. http://www.cancer.gov/types/myeloproliferative/hp/chronic-treatment-pdq#section/_9. Accessed on March 10, 2016